Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
There is increasing interest in the use of cell-free circulating tumor DNA (ctDNA) as a serum marker for therapy assessment in prostate cancer patients. Prostate cancer is characterized by relatively low numbers of mutations, and, in contrast to many other common epithelial cancers, commercially ava...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2019-01-01
|
| Series: | Disease Markers |
| Online Access: | http://dx.doi.org/10.1155/2019/5085373 |